Introduction
There is no firm epidemiologic evidence of a significant increase of Hodgkin's disease in patients with human immunodeficiency virus infection (HD-HIV). Nevertheless, of malignancies not included in the acquired immunodeficiency syndrome (AIDS) case definition, HD has one of the strongest and most consistently reported links with HIV [1] [2] [3] [4] [5] and there seems to be a growing consensus that this association is real.
The most common characteristics of HD-HIV at presentation are a significant proportion of histologically-mixed cellularity (MC) and lymphocyte-depleted (LD) subtypes, the very frequent occurrence of systemic symptoms, and a wide extent of disease, with the majority of patients belonging to stages III or IV [6] [7] [8] [9] [10] [11] [12] [13] [14] . The treatment of patients with HD-HIV is complicated by the underlying HIV infection. In several retrospective reports, the rate of complete response (CR) to chemotherapy varied from 44% to 79% and the median survival was between 8 and 20 months [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] (Table 1) . Many factors could explain this poor prognosis. The defective hematopoietic function frequently observed in HIV infection can exacerbate chemotherapy-induced myelosuppression, while a delay in administration of cytotoxic drugs or a reduction in their dosages may lessen the effect of the treatment. The severity of underlying HIVrelated disease may affect the prognosis regardless of the characteristics of HD. In fact, during chemotherapy, HIV-infected patients are particularly prone to severe opportunistic infections (OI). Already identified prognostic factors [6] are mainly related to the immunological status of patients (AIDS diagnosed prior to HD, low CD4+ lymphocyte counts). In our previous prospective study [16] in 17 patients with HD-HIV, the EBV (epirubicin, bleomycin and vinblastine) regimen in combination with zidovudine (AZT) yielded a 53% CR rate. EBV is a modification of the EBVP (epirubicin, bleomycin, vinblastine and prednisone) regimen, an ABVD-like regimen with low bone marrow toxicity developed by Zittoun et al. [17] for patients with 'primary' HD. We chose at that time, when hematopoietic growth factors were not yet available, not to use prednisone because of its potential for exerting an unfavourable effect on HIV infection. We observed a decreased occurrence of OI, but a similar objective response rate and survival time in comparison to the results previously observed in patients receiving standard chemotherapy without antiretroviral therapy. With the accumulated experience in the management of malignant lymphomas in HIV setting, we believed that prednisone could be safely used in patients with HD and HIV infection.
We report here the results of a phase II study combining the EBVP chemotherapy regimen (the previously employed EBV regimen with the prednisone addition) with antiretroviral therapy (AZT or dideoxinosyne, DDI) and granulocyte-colony stimulating factor (G-CSF) in HD-HIV patients who met the same inclusion criteria as those described in our previous trial [16] . The goal of this association was improvement of CR and survival rate; G-CSF was expected to reduce the hematological toxicity of chemotherapy and antiretroviral therapy to control evolution of the underlying HIV infection.
Patients and methods
From January 1993 to August 1997, 35 consecutive patients with H D -HIV were treated in a prospective study by the European Intergroup Study HD-HIV with the EBVP regimen and the concomitant antiretroviral therapy, with G-CSF support. The following inclusion criteria were required for enrollment: biopsy-proven HD; age between 16 and 65 years; stages III and IV disease; stages I and II disease with adverse prognostic factors, defined as the contemporary presence of bulky disease (tumoral mass larger than 10 cm) and B symptoms; life expectancy of more than one month. None of the patients had been previously treated with chemotherapy or irradiation, and none were currently self-injecting heroin, an exclusion-criterion for this study. The protocol was approved by the Institutional board and informed consent was obtained from each patient.
All patients had evidence of HIV infection, as determined by the presence of HIV antibodies by ELISA and confirmation by Western blot. All patients were registered at the Aviano Cancer Center and were treated in 15 different Italian (see also appendix) and three French institutions. The Rye modification of the Lukes and Butler classification was used to classify HD [18] . Distinct nodule and collagen band formation was required for diagnosing 'nodular sclerosing' subtype (NS), whereas lymph node biopsies characterised by increased fibrohistiocytoid stromal cells arranged in bundles were classified as MC subtype [12] , Tumors were classified as LD subtype in the presence of diagnostic features for either diffuse fibrosis or reticular subtype [19, 20] .
Staging
All patients were evaluated for extent of disease at diagnosis by physical examination; complete blood cell count, including CD4+ cell count; blood chemistry; chest radiographs; computed tomography scan of the abdomen; bone marrow aspirate and biopsy. The staging system according to the Ann Arbor classification was adopted.
Treatment
Patients were treated with epirubicin 70 mg/m 2 i.v. on day I, bleomycin 10 mg/m 2 i.v. on day 1, vinblastine 6 mg/m 2 i.v. on day 1 and prednisone 40 mg/m 2 p.o. from day 1 to day 5 (EBVP regimen). Courses were repeated every 21 days for six cycles. Cell blood count were to be obtained before administration of each cycle and was repeated once again between the 11th and 14th day following chemotherapy administration. The full dose of EBVP was administered when neutrophil granulocytes were higher than 2.5 x 10 9 /l , the leukocyte count higher than 3.5 x IO'/1 , or the platelet count was higher than 150 x 10 9 /l. When the full dose could not be given a one-week delay was recommended. The doses of epirubicin and vinblastine were reduced by 50% if after a week's delay the granulocyte count was between 1.6 and 2.5 x 10 9 /l, the leukocyte count was between 2.5 and 3.5 x I0 9 /l or the platelet count was between 100 and 150 x 10 9 /l. Treatment was delayed for another week and then resumed with the dose-reduction scheme above, if granulocyte count was lower than 1.6 x lO'/l, the leukocyte count was lower than 2.5 x I0 9 /I or the platelet count was lower than 100 x 10 AZT at the dose of 250 mg x 2/day or DDI at the dose of 200 (patients with body weight < 75 kg) or 300 (patients with body weight > 75 kg) mg x 2/day was given from the beginning of chemotherapy. DDI was the antiretroviral therapy of choice in patients who had failed previous treatment with AZT. DDI was the only antiretroviral drug as an alternative to AZT available at that time.
In an attempt to prevent the development of Pneumocystis Carinii pneumonia (PCP) and toxoplasmosis, all patients received cotrimoxazole 160/800 mg p.o. once a day seven days/week. In case of intolerance to cotrimoxazole, inhalative pentamidine (300 mg/monthly) was used.
G-CSF was given at the dose of 5 mcg/kg/day subcutaneously from day 6 to day 20 in all cycles.
Evaluation of antitumor response CR was defined as the complete absence of all measurable disease for at least four weeks. PR was defined as a 50% reduction in the sum of the product of the cross-sectional diameters of known lesions. Progressive disease (PD) was defined as a greater than 25% increase in measured lesions or the appearance of new lesions. Only patients who received chemotherapy for at least two cycles were considered evaluable for response. Response duration was computed from the first documentation of response to the day of documented disease recurrence or progression. Toxicity was evaluated according to standard World Health Organization (WHO) criteria.
Statistical methods
Survival was calculated from the date of starting therapy to the date of death or to last patient contact; disease-free survival (DFS) was calculated for patients with CR from first documentation of CR until relapse or the last known date on which the patient was free of disease. Time to treatment failure (TTF) was calculated from the beginning of treatment until relapse (for responding patients), disease progression (for patients known to progress), treatment-related death, withdrawal (for patients discontinuing treatment for any reason other than completion of the protocol without having either responded or progressed), or date last known to be alive, including all eligible patients and counting relapses, progression, treatment-related deaths and withdrawals (but not deaths resulting from unrelated causes) as events [21] . Survival curves were estimated by the Kaplan-Meier method [22] . Differences between subgroups were assessed by means of the log-rank test [23] . Multivariate analysis was performed using the proportional hazards model regression analysis of survival [24] .
Results
Thirty-five patients were enrolled in this study and all of them were eligible for evaluation of response and survival.
Pre-treatment characteristics of HD are shown in Table 2 . The median age was 34 years, and 83% of the patients had advanced-stage III-IV. Bone marrow was involved in 51% of the patients, liver in 11% and spleen in 31%. Forty-six percent had lymph node involvement only. Six patients (17%), all with B symptoms, had stage I-II with bulky disease. In particular, one patient had axillary bulky disease (IB), four patients had bulky disease in cervical lymph nodes and one patient had a subdiaphragmatic stage II with lymph nodal paraortic bulky disease. With reference to the histologic subtypes, 26% of patients had NS, 57% had MC, 8% had LD, and 8% had an unclassifiable subtype.
Pre-treatment immunological characteristics are shown in Table 3 . Nine patients had had AIDS indicators before their HD (PCP in four patients, esophageal candidiasis in three patients, atypical mycobacteriosis in one patient and Kaposi's sarcoma in one patient). When the diagnosis of HD was made, 23 of the 35 (68%) patients had no symptoms of HIV infection and 3 of 35 (9%) had ARC (AIDS-related complex), defined as the presence of constitutional symptoms (involuntary weight loss greater than 10%, fever, diarrhea for more than one month, oral infections that did not define the patients as having AIDS). For differentiation of HIV from HD systemic symptoms, weight loss and fever had to have been present for longer than six months to be denned as AIDS-related complex symptoms. Moreover, patients with B symptoms underwent extensive evaluation to exclude the presence of occult OIs.
Eighteen patients (51%) had received at least one antiretroviral drug before diagnosis of their HD, in particular 18 patients had been treated with AZT and two of them had received DDI after failure of AZT. At HD diagnosis the median CD4 + lymphocyte count was 219/mm 3 (range 6-812). Among the main laboratory findings at staging evaluation, the median hemoglobin value was 9.8 g/dl (range 5.8-14.8 g/dl), neutrophil granulocytes were 2146/dl (range 0.720-27.150/dl), and platelet count was 149,500/dl (range 25.000-384,000/dl).
Twenty-six patients completed the chemotherapy schedule. Chemotherapy was interrupted due to toxicity in one patient, major OI in three patients, HD progression in three patients, and patient refusal in two patients. The median number of courses per patient was 6 (range 3-6).
Overall, 32 of 35 (91%) patients had objective responses (95% confidence interval (95% CI): 77%-98%), and 26 of 35 (74%, 95% CI: 57%-87%) obtained CR lasting a median of 15.5 months (range 2.5-52). One patient who obtained CR after four cycles of EBVP and refused further chemotherapy received consolidation radiotherapy. With respect to results achieved in six patients with stage I-II and bulky disease, we observed five CR and one PR in the patient with subdiaphragmatic stage II disease. Only one of five patients with CR relapsed in initial bulky and new sites.
With a median follow-up of 22 months (range 3-56), 10 of the 26 patients obtaining CR experienced disease relapse (median time to relapse of six months, range 2.5-35), seven of them received second-line chemotherapy. In particular, three patients were treated with vinorelbine, two patient with MOPP (mechlorethamine, vincristine, procarbazine, and prednisone) and two patients with hybrid MOPP/ABV (doxorubicin, bleomycin and vinblastine). Only one of these patients obtained an 18-month PR with the hybrid MOPP/ABV regimen, while the other patients had disease progression. All relapsed patients died of HD progression, associated in one instance with PCP. Five additional complete responders also died, while still in remission from HD, of the following causes: three OI (one PCP, one CMV infection, one atypical mycobacteriosis), one of AIDS, not otherwise specified, and one of unknown cause. The median duration time of response in six patients with PR was five months. Two of these were treated with a second-line chemotherapy. A combination of ifosfamide, mitoxantrone and etoposide was used in one patient, in whom progressive disease was observed. The second patient, treated with MOPP, obtained a CR and is alive with no evidence of HD at nine months after the start of second-line treatment. Five of six patients, who obtained PR with EBVP, died, two of OI (one atypical myco- bacteriosis infection, one neurotoxoplasmosis), one of bacterial sepsis, one of cerebral haemorrhage and one of renal and liver failure. Three patients had no response to the EBVP regimen and died of HD progression, in one patient associated with OI (PCP). Overall survival and DFS curves are shown in Figures 1  and 2 . The median survival was 16 months (range 3-56) with a survival rate of 32% at three years. Median survival for the 26 patients who had a CR was 22 months whereas it was six months for the nine patients who failed to achieve CR (P = 0.0008). The rate of freedom from disease at three years is 53% (Figure 2 ) and the three-year treatment failure rate is 42% (Figure 3) .
In the evaluation of survival in terms of prestudy patient characteristics, no significant statistical association was noted when the following parameters were considered: age (^ 34 years vs. > 34), risk group (intravenous drug use vs. other risks); B symptoms (presence vs. absence); stage (I + II + III vs. IV); PS (0 + 1 vs. > 1); only lymphnodal involvement (presence vs. absence); spleen involvement (presence vs. absence); bone marrow involvement (presence vs. absence). On the other hand, we found a longer survival in patients with CD4+ count >200/mm 3 than in those with CD4+ <200/mm poorer survivals than patients without AIDS diagnoses (P -0.007), medians of 6 and 22 months, respectively. In addition, patients with lymphomatous liver involvement had shorter survivals than patients without involvement (P = 0.04), medians of 5 and 17 months, respectively. All factors significant in univariate analysis were included in a multivariate regression analysis for survival. Only CD4+ count ^ 200/mm 3 was found to be a significantly adverse prognostic factor (P = 0.05). Table 4 lists the toxicity observed in 190 administered cycles of chemotherapy. The most common side effect was bone marrow suppression. Overall,, we observed grade 3 and 4 leukopenia in seven and three patients, respectively, grade 4 thrombocytopenia in three patients and grade 3 and 4 anemia in two and one patients, respectively. Severe non-hematologic toxicity was rare: a grade 3 mucositis was observed in one patient, one patient had a grade 3 infection and a third patient a grade 3 hepatic toxicity.
Delays in chemotherapy cycles for one week occurred in one instance and reduction in the chemotherapy dose was required for three cycles in one patient. Twentythree patients received AZT and nine patients received DDI during the chemotherapy treatment period, as planned. Three patients refused concomitant antiretroviral therapy.
Overall, eight patients (23%) developed OI during or after chemotherapy (median follow-up 16 months). In particular, one OI (cytomegalovirus infection) occurred at the end of antineoplastic treatment in a patient who had been diagnosed with AIDS diagnosis at HD onset, while the other seven OI (three PCP, two atypical mycobacteriosis, one neurotoxoplasmosis, one cytomegalovirus infection) were observed in 26 patients without previous diagnoses of AIDS. Thus, 27% (7 of 26) of patients had an HIV-related illness, diagnostic of AIDS, during treatment and follow-up periods. In particular, only three of these patients developed OI during or within one month after the end of chemotherapy. We observed no worsening of the CD4+ cell count at the end of the combined therapy, with a median count before therapy of 219/mm 3 and afterward of 220/mm 3 .
Discussion
This is the largest study of patients with HD-HIV treated with concomitant antineoplastic and anti-HIV chemotherapy. In fact, besides our two prospective studies, only three other studies including a total of 27 patients have been reported, in abstract form [25] [26] [27] . In the past, most of these patients have been treated with classic combination chemotherapy regimens, i.e., MOPP and/or ABVD, and the underlying HIV was not usually treated concomitantly. However, the CR rate (median 57%) and overall survival (median 14 months) remained poorer than those of 'primary' HD (see Table 1 ).
In a previous study we showed that EBV chemotherapy and concomitant AZT was feasible, although the overall results were not satisfactory [16] . In an attempt to improve the latter results we designed this combined antineoplastic (using EBVP, i.e., EBV plus prednisone) and antiretroviral (AZT or DDI) approach, with primary use of G-CSF. In this study we confirmed the unfavourable features of HD-HIV at presentation, i.e., advanced stages and a high proportion of MC and LD subtypes, previously observed in ours [6, 16] and other series [7] [8] [9] [10] [11] [12] [13] . Moreover we observed an overall response rate of 91% with 74% of CR. The combination approach was again feasible and toxicity was moderate with no toxic deaths. The median survival was 16 months, with a survival rate of 32% and a DFS of 53% at 36 months, supporting the possibility of long-term control and possible cure of HD in approximately half of the patients with CR. We observed no significant differences in clinical characteristics of patients with more pronounced (i.e., CD4+ ^ 200,17 patients) and less pronounced (i.e., CD4+ > 200,18 patients) immunodeficiency.
Comparison of the results of our two consecutive prospective studies, i.e., EBVP + AZT or DDI and primary use of G-CSF vs. EBV + AZT, that were comparable with respect to clinical characteristics of patients, demonstrated no overall improvement in CR rate and survival in the current study. In fact, although the CR rate of the current regimen was higher than in the previous study (74% vs. 53%), this difference was not statistically significant, perhaps due to the relatively low number of patients in both studies (i.e., 35 vs. 17).
Interestingly, we observed no worsening of CD4+ cell count at the end of therapy in either study. Furthermore, the rate of 01 observed in the present study (8%) is not different from that observed in the previous study (6%), taking into consideration the same period of observation, indicating that prednisone had no adverse effect on OI occurrence. Moreover, no differences were observed in either survival or DFS at three years between the two studies (median survival 16 months vs. 11 months, and rate of survival 53% vs. 55%). Although the primary use of G-CSF allowed a decrease of delays in chemotherapy cycles due to leukopenia (0.5% of cycles vs. 5%), this did not positively impact on overall bone marrow toxicity, CR rate or overall outcome.
In the present study, we have also confirmed the importance of the underlying HIV-related prognostic factor (i.e., CD4+ lymphocyte count). In fact, the patients with CD4+ counts >200/mm 3 had better survivals than patients with CD4+ count ^ 200/mm 3 (median survival 30 vs. 6 months, P = 0.001), and HD-related prognostic factors were found to be superimposable in the two groups of patients. On the other hand the DFS in the two groups of patients were not different.
It must be stressed that the present study was based on a relatively ineffective anti-HIV chemotherapy, and in future studies the use of more efficacious anti-HIV drugs (including protease inhibitors) should be considered. Moreover, taking into consideration the reported unfavourable HD features in HIV setting, we should test more intensive and potentially more efficacious chemotherapy regimens, for example the so-called 'Stanford V regimen [28] .
In conclusion, in the present study we demonstrated that the combined antineoplastic and antiretroviral treatment is feasible. Although the CR rate obtained was satisfactory, the relapse rate was high. Furthermore, comparison of the results of our two consecutive prospective studies demonstrated no overall improvement of the current trial as far as the CR rate and survival were concerned. Moreover, with the combined approach that we used (EBVP and AZT or DDI) no apparent advantage was obtained from the primary use of hematopoietic growth factor.
